XML 43 R29.htm IDEA: XBRL DOCUMENT v3.19.1
Company Operations by Product, Customer and Geographic Area
12 Months Ended
Dec. 31, 2018
Segment Reporting [Abstract]  
Company Operations by Product, Customer and Geographic Area
Company Operations by Product, Customer and Geographic Area 
The Company has determined that we operate in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the interim CEO. The interim CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 
The following table presents a summary of total revenues by these products for the twelve months ended December 31, 2018, 2017, and 2016
 Revenue by Product:
 
2018
 
2017
 
2016
 
 
 
 
 
 
 
Bloxiverz
 
$
20,850

 
$
45,596

 
$
82,896

Vazculep
 
42,916

 
38,187

 
39,796

Akovaz
 
33,759

 
80,617

 
16,831

Noctiva
 
1,204

 

 

Other
 
2,694

 
8,441

 
7,699

Total product sales
 
101,423

 
172,841

 
147,222

License revenue
 
1,846

 
404

 
3,024

Total revenues
 
$
103,269

 
$
173,245

 
$
150,246

 
Concentration of credit risk with respect to accounts receivable is limited due to the high credit quality comprising a significant portion of the Company’s customers. Management periodically monitors the creditworthiness of our customers and believes that we have adequately provided for any exposure to potential credit loss.
The following table presents a summary of total revenues by significant customer for the twelve months ended December 31, 2018, 2017, and 2016
Revenue by Significant Customer:
 
2018
 
2017
 
2016
 
 
 
 
 
 
 
Customer A
 
$
26,794

 
$
44,762

 
$
51,648

Customer B
 
25,413

 
37,965

 
39,359

Customer C
 
18,620

 
25,691

 
30,916

Customer D
 
9,653

 
53,342

 
17,728

Others
 
20,943

 
11,081

 
7,571

Total product sales
 
101,423

 
172,841

 
147,222

License revenue
 
1,846

 
404

 
3,024

Total revenues
 
$
103,269

 
$
173,245

 
$
150,246


As of December 31, 2018, the Company had four customers, each of which are substantial wholesale distributors, and accounted for 10% or more of the accounts receivable balance. One customer accounted for 32%, or $3,571, a second customer accounted for 24% or $2,755, a third customer accounted for 24% or $2,789, and a fourth customer accounted for 10% or $1,174. As of December 31, 2018, the Company had no significant past due account receivable balances.
The following table summarizes revenues by geographic region for the twelve months ended December 31, 2018, 2017, and 2016:
Revenue by Geographic Region:
 
2018
 
2017
 
2016
 
 
 

 
 

 
 

United States
 
$
101,423

 
$
172,841

 
$
147,283

Ireland
 
1,846

 
404

 
2,963

Total revenues
 
$
103,269

 
$
173,245

 
$
150,246


Currently we depend on a single contract manufacturing organization for the manufacture of Bloxiverz, Vazculep and Noctiva and two contract manufacturing organizations for the manufacture of Akovaz, from which we derive a majority of our revenues. Additionally, we purchase certain raw materials used in our products from a limited number of suppliers, including a single supplier for certain key ingredients.

Non-monetary long-lived assets primarily consist of property and equipment, goodwill and intangible assets. The following table summarizes non-monetary long-lived assets by geographic region as of December 31, 2018, 2017, and 2016:
Long-lived Assets by Geographic Region:
 
2018
 
2017
 
2016
 
 
 

 
 

 
 

United States
 
$
27,761

 
$
116,536

 
$
42,021

France
 
1,365

 
2,257

 
2,524

Ireland
 
6,028

 
1,360

 
202

Total
 
$
35,154

 
$
120,153

 
$
44,747